Nebojsa Janjic
Chairman at Crestone, Inc.
Profile
Nebojsa Janjic was the founder of Replidyne, Inc. which was founded in 2000 where he held the position of Secretary & Chief Scientific Officer until 2008.
He is currently the Chairman at Crestone, Inc. and the Chief Science Officer at SomaLogic Operating Co., Inc. since 2009.
Dr. Janjic was a Senior Director-Drug Discovery at NeXstar Pharmaceuticals, Inc. from 1992 to 1999 and also held the position of Chief Science Officer at SomaLogic, Inc. Dr. Janjic received his undergraduate and doctorate degrees from the University of Washington.
Nebojsa Janjic active positions
Companies | Position | Start |
---|---|---|
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Chief Tech/Sci/R&D Officer | 31/12/2008 |
Crestone, Inc. | Chairman | - |
Former positions of Nebojsa Janjic
Companies | Position | End |
---|---|---|
STANDARD BIOTOOLS INC. | Chief Tech/Sci/R&D Officer | 04/01/2024 |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Founder | 07/12/2008 |
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | Corporate Officer/Principal | 31/12/1998 |
Training of Nebojsa Janjic
University of Washington | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Listed companies | 1 |
---|---|
STANDARD BIOTOOLS INC. | Commercial Services |
Private companies | 4 |
---|---|
NeXstar Pharmaceuticals, Inc.
NeXstar Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology NeXstar Pharmaceuticals, Inc. was a commercial biopharmaceutical company engaged in the discovery, development, manufacture and marketing of proprietary pharmaceutical products to treat life-threatening and other serious diseases. The firm was located in Boulder, CO. | Health Technology |
Replidyne, Inc.
Replidyne, Inc. BiotechnologyHealth Technology Replidyne, Inc. is a biopharmaceutical company focused on developing and commercializing innovative anti-infective products. The company's new drug application (NDA) for its lead product, faropenem medoxomil, has been accepted for standard review by the FDA. Faropenem medoxomil is an orally available antibiotic for the treatment of community acquired infections, such as respiratory tract infections. Other development programs include higher dose/shorter course therapy, additional ndications for adults and a pediatric formulation of faropenem medoxomil. The ompany’s pipeline also includes a topical anti-bacterial product, REP8839, hich has a novel mechanism of action for addressing the major challenge of ethicillin-resistant Staphylococcus aureus (MRSA). The company also has iscovery programs directed to the inhibition of bacterial DNA replication, which could result in therapies to treat a wide range of antibiotic-resistant bacteria. The company is headquartered in Louisville, CO | Health Technology |
SomaLogic Operating Co., Inc.
SomaLogic Operating Co., Inc. Medical SpecialtiesHealth Technology SomaLogic Operating Co., Inc. engages in the development of technologies used in the areas of diagnostics, clinical research, and pharmaceutical development. It offers protein biomarker systems for applications in drug discovery, therapeutic treatments, and wellness monitoring. The firm's products and services include SOMAscan service, SOMAscan at the institution, individual SOMAscan reagents, SOMAmer discovery service, SomaLogic CLIA laboratory, and technical support. The company was founded by Larry Gold and David Brunel in 2000 and is headquartered in Boulder, CO. | Health Technology |
Crestone, Inc. |
- Stock Market
- Insiders
- Nebojsa Janjic